WYNNE, Ark., July 15, 2025 (GLOBE NEWSWIRE) -- Mueller Streamline Co. has announced an investment of more than $7 million to expand its manufacturing facility in Wynne, Arkansas. The expansion is expected to create 60 new jobs over two years. “Since our acquisition of Halstead Industries in 1998, our companies have not only supported the local economies of the City of Wynne and Cross County, but they have also invested in further expansion across the State of Arkansas. Among other initiatives, we built a ne ...

Financial Performance - Net income was $113.5 million, or $1.32 per diluted share, compared to $119.5 million, or $1.38 per diluted share in 1Q25[24, 25] - Adjusted Pre-Provision Net Revenue (PPNR) totaled $167.9 million, up $5.5 million compared to 1Q25[24, 25] - Net Interest Margin (NIM) was 3.49%, up 6 bps compared to 1Q25[24, 25] - Efficiency ratio was 54.91%, improved 31 bps compared to prior quarter[24, 25] Balance Sheet - Total assets reached $35.2 billion[10] - Loans totaled $23.5 billion, up $364 million, or 6% LQA[10, 25, 29] - Deposits totaled $29.0 billion, down $148 million, or 2% LQA[10, 25, 36] - CET1 ratio was estimated at 14.03%, down 45 bps linked-quarter; TCE ratio at 9.84%, down 17 bps linked-quarter[10, 24, 25] Asset Quality - Criticized commercial loans totaled $569 million, or 3.15% of total commercial loans, down $25 million from $594 million, or 3.35% of total commercial loans, in prior quarter[38, 39] - Nonaccrual loans totaled $95 million, or 0.40% of total loans, down $9 million from $104 million, or 0.45% of total loans, in prior quarter[38, 39] - ACL coverage solid at 1.45%, compared to 1.49% in prior quarter[25, 41] Forward Guidance - Expect EOP loans at 12/31/25 to be up low single digits from 12/31/24 levels[74] - Expect NII (te) to be up between 3%-4% from FY24; expect modest NIM expansion throughout 2H25[74] - Expect noninterest income to be up 9%-10% from FY24 noninterest income[74]

Financial Performance - Q2 2025 organic revenue grew by 30%[9] - Q2 Non-GAAP Adj EBITA increased by 41% to $6138 million with a 153% margin[10] - Q2 Non-GAAP adjusted diluted EPS increased by 51% to $205[10] - The company repurchased $142 million in shares in Q2 and $223 million year-to-date[10] Revenue Breakdown - Media & Advertising and Precision Marketing accounted for 68% of total revenue with combined organic growth exceeding 7%[9] - Total revenue for the second quarter was $40156 million a 42% increase[11] - Year-to-date revenue reached $77060 million a 30% increase[11] Strategic Initiatives - The Interpublic (IPG) Transaction cleared antitrust review by the US Federal Trade Commission in late June 2025 with closing expected in the second half of 2025[9] - The company achieved a $250 million year-to-date improvement in the use of operating capital[10]

AUDUBON, Pa., July 15, 2025 (GLOBE NEWSWIRE) -- Globus Medical, Inc. (NYSE: GMED), a leading musculoskeletal solutions company, today announced the expanded Excelsius™ navigation capabilities of its next-generation oscillating system, DuraPro™, as the latest addition to the Power Portfolio, designed to advance procedural workflows through safety features and efficiency. “Our goal is to revolutionize the $550 million high-speed drill market with the introduction of innovative, next generation oscillation,” s ...

Transaction Update: AAM Stockholders Approve Proposed CombinationDETROIT, July 15, 2025 /PRNewswire/ -- American Axle & Manufacturing Holdings, Inc. ("AAM"), (NYSE: AXL) today announced that at a special meeting (the "Special Meeting") of its stockholders ("AAM Stockholders") held in connection with AAM's recommended offer to acquire the entire issued and to be issued share capital of Dowlais Group plc ("Dowlais"), (the "Combination"), AAM Stockholders approved all proposals related to the Combination as de ...

Core Insights - Kestra Medical Technologies, Ltd. reported strong financial results for Q4 and FY25, driven by increased demand for its ASSURE® cardiac recovery system [3][5][6] - The company achieved a total revenue of $59.8 million in FY25, marking a 115% increase compared to FY24 [5][6] - Gross margin improved significantly, reaching 44.3% in Q4 FY25 and 40.5% for FY25, compared to 13.9% and 1.3% in the prior periods respectively [6][15] Financial Performance - Q4 FY25 revenue was $17.2 million, a 71% increase year-over-year, with 3,903 prescriptions written for the ASSURE® system, up 43% from the previous year [6][7] - The company generated a gross profit of $7.6 million in Q4 FY25, compared to $1.4 million in the same period last year [7][20] - GAAP net loss for Q4 FY25 was $51.1 million, compared to a loss of $22.3 million in Q4 FY24 [7][21] Operational Highlights - The company wrote a total of 13,193 prescriptions for the ASSURE® system in FY25, a 72% increase from FY24 [15] - Operating expenses for FY25 were $130.6 million, up from $85.4 million in FY24, largely due to increased commercial and revenue cycle resources [15][21] - Cash and cash equivalents stood at $237.6 million as of April 30, 2025, a significant increase from $8.2 million a year earlier [18] Future Outlook - Kestra has initiated revenue guidance for FY26 at $85 million, representing a 42% increase compared to FY25 [6][9] - The company remains focused on innovation and enhancing prescriber and patient support to drive market expansion [3][6]

Company Overview - Anixa Biosciences, Inc. (NASDAQ: ANIX) focuses on developing immunotherapies for cancer through two main platforms: a CAR-T program aimed at solid tumors and a vaccine technology that generates tumor-specific antigens [1]. Partnerships - Anixa has established partnerships with the Moffitt Cancer Center, which may enhance its research and development capabilities in the field of cancer immunotherapy [1].

Key Takeaways JBL plans a multi-year $500M investment to expand U.S. AI and cloud data center manufacturing capacity. CLS sees growth in its CCS segment, fueled by strong demand for 400G/800G switches and IoT-edge offerings. Estimates show stronger EPS growth for CLS, while JBL shows rising cash flow and more attractive valuation.Celestica Inc. (CLS) and Jabil Inc. (JBL) are two leading players in the electronics manufacturing services (EMS) industry. Jabil offers electronics design, production, product m ...

I I think you're already seeing uh stable coins are being used. They're used as the base pair for basically all crypto exchanges. So whenever anyone wants to go in or out of crypto, they do it using stable coins.Now you're also seeing them being used by merchants to accept payments. It is a new kind of payment rail. It's faster, it's smoother, it's cheaper, it's global, uh it's based on blockchain technology.So I do think that this is a huge emerging use case for stable coins is this being the new payment r ...

Standard Chartered says stablecoins overshadowed bitcoin in discussions; $750 billion market size could trigger macroeconomic shifts https://t.co/VmViO1SqJa ...